Delaware held that plaintiff Amarin Pharma failed to plead facts sufficient to show that Hikma Pharmaceuticals’ carved-out product label and/or public marketing statements induced infringement of Amarin’s patents.
Delaware held that plaintiff Amarin Pharma failed to plead facts sufficient to show that Hikma Pharmaceuticals’ carved-out product label and/or public marketing statements induced infringement of Amarin’s patents.
On January 4, 2022, the District Court for the District of Delaware granted Hikma Pharmaceuticals USA Inc.’s (“Hikma”) motion to dismiss Amarin Pharma Inc.’s (“Amarin”) infringement.
The heightening consciousness amidst customers internationally brought about by the prevalence of incessant ailments is fuelling the growth of the Omega-3 segment.
Hikma Pharmaceuticals USA Inc.'s generic heart drug does not infringe three patents underlying Amarin Pharma Inc.'s drug Vascepa, a Delaware federal judge ruled Tuesday, breaking with the recommendation from a magistrate judge.